Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / syros pharmaceuticals entering a decisive era with a

SYRS - Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Syros Pharmaceuticals Inc.

2024-07-02 12:56:55 ET

Summary

  • Syros Pharmaceuticals focuses on developing therapies for myeloid cancers.
  • The main pipeline candidate is tamibarotene, with positive signals in phase 2 trial and a key data readout coming in Q4 2024.
  • Financially, SYRS has $112.2 million in assets, but faces a high cash burn rate and potential need for more financing.

Topline Summary and Update

For further details see:

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout
Stock Information
Company Name: Syros Pharmaceuticals Inc.
Stock Symbol: SYRS
Market: NASDAQ
Website: syros.com
Menu
SYRS SYRS Quote SYRS Short SYRS News SYRS Articles SYRS Message Board
Get SYRS Alerts

News, Short Squeeze, Breakout and More Instantly...